Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Interest & Investment Income (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Interest & Investment Income data on record, last reported at $3.5 million in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 2.31% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $13.1 million, up 7.0%, while the annual FY2024 figure was $12.6 million, 27.55% up from the prior year.
  • Interest & Investment Income reached $3.5 million in Q3 2025 per STOK's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.8 million in Q2 2025 and bottomed at $104000.0 in Q1 2022.
  • Average Interest & Investment Income over 4 years is $2.4 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: surged 1922.12% in 2023, then dropped 2.31% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $1.5 million in 2022, then surged by 74.92% to $2.6 million in 2023, then grew by 14.8% to $3.0 million in 2024, then grew by 16.6% to $3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $3.5 million in Q3 2025, $3.8 million in Q2 2025, and $2.9 million in Q1 2025.